LNTH
HealthcareLantheus Holdings, Inc. · Drug Manufacturers - Specialty & Generic · $7B
What is Lantheus Holdings, Inc.?
Lantheus Holdings is a mid-cap healthcare company focused on diagnostic imaging and radiotherapeutic products. Operating globally, it helps clinicians detect and treat heart disease, cancer, and other serious conditions through a portfolio of nuclear medicine and ultrasound agents.
Lantheus develops, manufactures, and commercializes diagnostic and therapeutic agents used in nuclear medicine, ultrasound imaging, and oncology. Its products help physicians visualize disease — from blocked blood flow in the heart to metastatic prostate cancer — and in some cases deliver targeted radiotherapy. Revenue comes from selling these specialized agents to hospitals, imaging centers, and healthcare providers worldwide. The company also invests in next-generation AI-assisted imaging software and pipeline radiopharmaceuticals.
Lantheus Holdings was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
- DEFINITY — microbubble ultrasound enhancing agent for cardiac imaging
- PYLARIFY — PSMA PET imaging agent for prostate cancer detection
- TechneLite — technetium generator for nuclear medicine procedures
- AZEDRA — radiotherapeutic for rare neuroendocrine tumors
- PYLARIFY AI — AI software for standardized PSMA PET/CT image analysis
Is LNTH a Good Stock to Buy?
UQS Score rates LNTH as Good overall, reflecting a balanced but nuanced profile across its five scoring pillars.
The Risk pillar comes in at a Good rating, suggesting the company carries a manageable financial and operational risk profile relative to sector peers. Valuation is rated Attractive, meaning the stock does not appear richly priced compared to its fundamentals — a notable characteristic in the healthcare space. Quality also registers as Good, pointing to a reasonably sound underlying business.
Growth is rated Weak, which signals that near-term expansion may be limited or decelerating. The Moat pillar sits at Neutral, indicating that competitive advantages, while present, are not yet among the strongest in the sector.
Pro members can view the exact pillar breakdown and full financial metrics behind each rating. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LNTH pay dividends?
No — Lantheus Holdings, Inc. does not currently pay a dividend.
Lantheus does not currently pay a dividend. This is common among specialty healthcare and radiopharmaceutical companies that prioritize reinvesting capital into pipeline development, manufacturing capabilities, and commercial expansion. Investors seeking income from LNTH would need to look elsewhere, but the absence of a dividend may reflect ongoing investment in long-term growth opportunities.
When does LNTH report earnings?
Lantheus Holdings reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results have reflected both the commercial momentum of its flagship imaging agents and the ongoing costs of pipeline investment. Revenue trends and profitability can shift meaningfully quarter to quarter given the specialized nature of radiopharmaceutical supply chains.
For the most recent quarter's results and guidance, visit Lantheus Holdings' investor relations page directly.
LNTH Price History
+236.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Lantheus Holdings, Inc.?
Based on Lantheus Holdings, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
LNTH Long-term Outlook
The UQS Growth pillar rating of Weak suggests that near-term revenue or earnings expansion may face headwinds, whether from competitive pressure, product lifecycle dynamics, or pipeline timing. However, the Attractive Valuation rating indicates the market may already be pricing in a degree of caution. The Good Risk rating provides some confidence that the company is not in financial distress. Longer-term trajectory will likely depend on pipeline execution and the commercial uptake of newer products.
Growth drivers
- Expanding adoption of PYLARIFY in prostate cancer imaging across healthcare systems
- Pipeline advancement of next-generation radiopharmaceutical and AI-assisted imaging assets
- Potential label expansions and new indications for existing diagnostic agents
Key risks
- Weak Growth pillar signals near-term revenue momentum may be limited
- Neutral Moat rating reflects competitive vulnerability in specialty imaging markets
- Radiopharmaceutical supply chain complexity could pressure margins or product availability
LNTH vs Peers
Lantheus operates in a specialized corner of healthcare, but it shares some competitive overlap with other specialty pharmaceutical and diagnostics companies.
Amneal focuses broadly on generics and specialty pharmaceuticals, giving it a wider product base but less concentration in nuclear medicine imaging.
Indivior specializes in addiction treatment medicines, making it a specialty pharma peer by structure but with a very different therapeutic focus than Lantheus.
Bausch Health is a diversified specialty pharma company with a broad portfolio spanning eye health and gastroenterology, contrasting with Lantheus's imaging-centric model.
Frequently Asked Questions
What does Lantheus Holdings do?
Lantheus develops and sells diagnostic imaging agents and radiotherapeutic products used by clinicians worldwide. Its portfolio spans ultrasound enhancers, nuclear medicine generators, and oncology-focused PET imaging agents. The company also invests in AI-based imaging software and a pipeline of next-generation radiopharmaceuticals targeting cancer and cardiovascular disease.
Does LNTH pay dividends?
Lantheus does not currently pay a dividend. The company reinvests its capital into pipeline development and commercial operations rather than returning cash to shareholders through distributions. Investors focused on income may want to factor this into their portfolio planning.
When does LNTH report earnings?
Lantheus reports earnings quarterly, in line with standard US-listed company practice. Specific dates are not covered by our data source. For the most current earnings schedule, check Lantheus Holdings' official investor relations page.
Is LNTH a good stock to buy?
UQS Score rates LNTH as Good overall. The Valuation pillar is Attractive and Risk is Good, which are positive signals. However, the Growth pillar is Weak and Moat is Neutral, suggesting some caution is warranted. The full pillar breakdown is available to Pro members for a more complete picture.
Is LNTH overvalued?
Based on the UQS Valuation pillar, LNTH is rated Attractive — meaning the stock does not appear overpriced relative to its fundamentals. This is a relative assessment within the healthcare sector and should be considered alongside the company's growth and moat profile before drawing conclusions.
How does LNTH compare to its competitors?
Lantheus occupies a specialized niche in nuclear medicine and radiopharmaceutical imaging, which differentiates it from broader specialty pharma peers like Amneal or Bausch Health. Its focus on diagnostic agents and targeted radiotherapy gives it a distinct product profile, though its Moat pillar rating of Neutral suggests competitive advantages are not yet dominant.
What is LNTH's market cap bracket?
Lantheus Holdings is classified as a mid-cap company. This places it in a range that typically offers more growth potential than large-caps but with greater volatility than the largest healthcare names. Mid-cap status also means it may receive less analyst coverage than mega-cap peers.
Who founded Lantheus Holdings?
Lantheus Holdings was incorporated in 2015, though its operational roots trace back further through predecessor entities in the nuclear medicine space. Detailed founding history is widely available through the company's official disclosures and public filings.
Is LNTH a long-term quality investment?
As a long-term quality indicator, LNTH's Good UQS Score reflects a reasonably sound business with an Attractive valuation and manageable risk. The Weak Growth and Neutral Moat ratings are factors to monitor over time. Pro members can access the complete analysis to assess long-term quality more thoroughly.
What is the main competitive advantage of Lantheus Holdings?
Lantheus benefits from specialized manufacturing capabilities in radiopharmaceuticals and an established commercial presence in nuclear medicine imaging. Products like PYLARIFY have carved out a meaningful role in prostate cancer diagnostics. However, the UQS Moat pillar rates these advantages as Neutral, indicating room for further differentiation.
What sector does LNTH belong to?
Lantheus Holdings operates in the Healthcare sector, specifically within the specialty pharmaceuticals and radiopharmaceutical diagnostics space. It sits at the intersection of nuclear medicine, oncology imaging, and therapeutic radiopharmaceuticals — a technically complex and regulated segment of healthcare.
Is LNTH a growth stock or value stock?
Based on UQS pillar labels, LNTH leans toward value characteristics — the Valuation pillar is Attractive while the Growth pillar is Weak. This combination suggests the stock may appeal more to investors seeking reasonable pricing than those chasing high near-term growth momentum.
Unlock Full LNTH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare LNTH against sector peers side by side
- ✓See the full risk and valuation breakdown in detail
- ✓Track score changes over time with Pro alerts
Pro Analysis
LNTH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 62.9 | 77.1 | 46.0 | 36.1 | 97.9 | 68.5 | -0.8 |
| May 21, 2026 | 63.7 | 77.9 | 46.0 | 36.1 | 97.9 | 72.1 | -0.3 |
| May 19, 2026 | 64.0 | 78.3 | 46.0 | 36.1 | 97.9 | 73.8 | +0.1 |
| May 16, 2026 | 63.9 | 78.2 | 46.0 | 36.1 | 97.9 | 73.2 | +0.3 |
| May 15, 2026 | 63.6 | 77.8 | 46.0 | 36.1 | 97.9 | 71.7 | +2.2 |
| May 7, 2026 | 61.4 | 75.7 | 46.0 | 35.6 | 78.3 | 80.5 | -0.1 |
| May 3, 2026 | 61.5 | 75.7 | 46.0 | 35.6 | 78.3 | 81.5 | -0.1 |
| Apr 26, 2026 | 61.6 | 75.7 | 46.0 | 35.6 | 78.3 | 81.9 | +0.1 |
| Apr 22, 2026 | 61.5 | 75.7 | 46.0 | 35.6 | 78.3 | 81.2 | +0.1 |
| Apr 19, 2026 | 61.4 | 75.7 | 46.0 | 35.4 | 78.3 | 81.3 | -0.5 |
LNTH — Pillar Breakdown
Quality
— 77.1/100 (25%)Lantheus Holdings, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 36.1/100 (20%)Lantheus Holdings, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 97.9/100 (15%)Lantheus Holdings, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 68.6/100 (15%)Lantheus Holdings, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Lantheus Holdings, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LNTH.
Score Composition
Financial Data
More Stock Analysis
How is the LNTH UQS Score Calculated?
The UQS (Unified Quality Score) for Lantheus Holdings, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Lantheus Holdings, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Lantheus Holdings, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.